A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

被引：0

作者：

Terpos, Evangelos ^{[1
]}

Kastritis, Efstathios ^{[2
]}

Symeonidis, Argiris ^{[3
]}

Pouli, Anastasia ^{[4
]}

Delimpasi, Sosana ^{[5
]}

Katodritou, Eirini ^{[6
]}

Hatzimichael, Eleftheria ^{[7
]}

Ntanasis-Stathopoulos, Ioannis ^{[8
]}

Malandrakis, Panagiotis ^{[8
]}

Fotiou, Despina ^{[8
]}

Migkou, Magdalini ^{[8
]}

Theodorakakou, Foteini ^{[8
]}

Spiliopoulou, Vasiliki ^{[8
]}

Syrigou, Rodanthi ^{[8
]}

Eleutherakis-Papaiakovou, Evangelos ^{[2
]}

Manousou, Kyriaki ^{[9
]}

Gavriatopoulou, Maria

Dimopoulos, Meletios A. ^{[2
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Drosia, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] Univ Patras, Sch Med, Hematol Div, Dept Internal Med, Patras, Greece

[4] St Savvas Oncol Hosp, Hematol Dept, Athens, Greece

[5] Gen Hosp Evangelismos, Athens, Greece

[6] Theagenio Canc Hosp, Dept Hematol, Thessaloniki, Greece

[7] Univ Ioannina, Dept Hematol, Fac Med, Ioannina, Greece

[8] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[9] Hlth Data Specialists, Dublin, Ireland

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation [J].

Ocio, Enrique M. ;

Perrot, Aurore ;

Bories, Pierre ;

San-Miguel, Jesus F. ;

Blau, Igor W. ;

Karlin, Lionel ;

Martinez-Lopez, Joaquin ;

Wang, Song-Yau ;

Bringhen, Sara ;

Marcatti, Magda ;

Mateos, Maria-Victoria ;

Rodriguez-Otero, Paula ;

Oliva, Stefania ;

Nogai, Axel ;

Le Roux, Nadia ;

Dong, Liyan ;

Mace, Sandrine ;

Gassiot, Matthieu ;

Fitzmaurice, Thomas ;

Oprea, Corina ;

Moreau, Philippe .

LEUKEMIA, 2023, 37 (07) :1521-1529

[22] Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation [J].

Enrique M. Ocio ;

Aurore Perrot ;

Pierre Bories ;

Jesus F. San-Miguel ;

Igor W. Blau ;

Lionel Karlin ;

Joaquin Martinez-Lopez ;

Song-Yau Wang ;

Sara Bringhen ;

Magda Marcatti ;

María-Victoria Mateos ;

Paula Rodriguez-Otero ;

Stefania Oliva ;

Axel Nogai ;

Nadia Le Roux ;

Liyan Dong ;

Sandrine Macé ;

Matthieu Gassiot ;

Thomas Fitzmaurice ;

Corina Oprea ;

Philippe Moreau .

Leukemia, 2023, 37 :1521-1529

[23] Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ [J].

Manier, Salomon ;

Dimopoulos, Meletios-Athanasios ;

Leleu, Xavier ;

Moreau, Philippe ;

Cavo, Michele ;

Goldschmidt, Hartmut ;

Orlowski, Robert Z. ;

Tron, Muriel ;

Tekle, Christina ;

Bregeault, Marie-France ;

Shafer, Andrea ;

Beksac, Meral ;

Facon, Thierry .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 :S290-S291

[24] Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial [J].

O'Donnell, Elizabeth ;

Mo, Clifton ;

Yee, Andrew J. ;

Nadeem, Omar ;

Laubach, Jacob ;

Rosenblatt, Jacalyn ;

Munshi, Nikhil ;

Midha, Shonali ;

Cirstea, Diana ;

Chrysafi, Pavlina ;

Horick, Nora ;

Richardson, Paul G. ;

Raje, Noopur .

LANCET HAEMATOLOGY, 2024, 11 (06) :e415-e424

[25] Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial [J].

Leleu, Xavier ;

Hulin, Cyrille ;

Lambert, Jerome ;

Bobin, Arthur ;

Perrot, Aurore ;

Karlin, Lionel ;

Roussel, Murielle ;

Montes, Lydia ;

Cherel, Brieuc ;

Chalopin, Thomas ;

Slama, Borhane ;

Chretien, Marie-Lorraine ;

Laribi, Kamel ;

Dingremont, Claire ;

Roul, Christophe ;

Mariette, Clara ;

Rigaudeau, Sophie ;

Calmettes, Claire ;

Dib, Mamoun ;

Tiab, Mourad ;

Vincent, Laure ;

Delaunay, Jacques ;

Santagostino, Alberto ;

Macro, Margaret ;

Bourgeois, Emmanuelle ;

Orsini-Piocelle, Frederique ;

Gay, Julie ;

Bareau, Benoit ;

Bigot, Noemie ;

Vergez, Francois ;

Lebreton, Pierre ;

Tabrizi, Reza ;

Waultier-Rascalou, Agathe ;

Frenzel, Laurent ;

Le Calloch, Ronan ;

Chalayer, Emilie ;

Braun, Thorsten ;

Lachenal, Florence ;

Corm, Selim ;

Kennel, Celine ;

Belkhir, Rakiba ;

Blade, Jean-Sebastien ;

Joly, Bertrand ;

Richez-Olivier, Valentine ;

Gardeney, Helene ;

Demarquette, Helene ;

Robu-Cretu, Daniela ;

Garderet, Laurent ;

Newinger-Porte, Muriel ;

Kasmi, Amine .

NATURE MEDICINE, 2024, 30 (08) :2235-2241

[26] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) [J].

O'Donnell, Elizabeth K. ;

Mo, Clifton C. ;

Nadeem, Omar ;

Yee, Andrew J. ;

Branagan, Andrew R. ;

Laubach, Jacob ;

Gammon, Marilyn T. ;

Lively, Kathleen J. ;

Packer, Lisette ;

Harrington, Cynthia C. ;

Agyemang, Emerentia ;

Rosenblatt, Jacalyn ;

Horick, Nora K. ;

Richardson, Paul G. ;

Raje, Noopur .

BLOOD, 2022, 140 :7282-7283

[27] A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) [J].

O'Donnell, Elizabeth K. ;

Mo, Clifton C. ;

Yee, Andrew J. ;

Nadeem, Omar ;

Branagan, Andrew R. ;

Laubach, Jacob ;

Rosenblatt, Jacalyn ;

Horick, Nora ;

Richardson, Paul G. ;

Raje, Noopur ;

Cirstea, Diana .

BLOOD, 2023, 142

[28] Bortezomib and Dexamethasone Therapy for Newly Diagnosed Patients With Multiple Myeloma Complicated by Renal Impairment [J].

Li, Jian ;

Zhou, Dao-Bin ;

Jiao, Li ;

Duan, Ming Hui ;

Zhang, Wei ;

Zhao, Yong Qiang ;

Shen, Ti .

CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (05) :394-398

[29] Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study [J].

Orlowski, Robert Z. ;

Dimopoulos, Meletios-Athanasios ;

Leleu, Xavier ;

Liu, Zhuogang ;

Ishida, Tadao ;

Hajek, Roman ;

Spicka, Ivan ;

Romejko-Jarosinska, Joanna ;

Vorobyev, Vladimir I. ;

Besemer, Britta ;

Besisik, Sevgi ;

Robak, Pawel ;

Goldschmidt, Hartmut ;

Martin, Thomas ;

Mohty, Mohamad ;

Mace, Sandrine ;

Kodas, Ercem ;

Tekle, Christina ;

Shafer, Andrea ;

Moreau, Philippe .

BLOOD, 2024, 144 :772-772

[30] Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma [J].

Kristian T. Andersen ;

Maja Hinge ;

Agoston Gyula Szabo ;

Erik Segel ;

Tina Ormstrup ;

Paw C. Holdgaard ;

Niels Pallisgaard ;

Gitte Kerndrup ;

Torben Plesner .

Clinical Hematology International, 2020, 2 (1) :35-39

← 1 2 3 4 5 →